Histone Deacetylase Inhibitors in Cancer Therapy

Author(s): Yijie Sun, Yanyi Sun, Saichao Yue, Yaohe Wang, Fanghui Lu*

Journal Name: Current Topics in Medicinal Chemistry

Volume 18 , Issue 28 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.

Keywords: Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment, RNA, DNA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [2420 - 2428]
Pages: 9
DOI: 10.2174/1568026619666181210152115
Price: $65

Article Metrics

PDF: 63
PRC: 1